Changing management in patients with papillary thyroid cancer

Current Treatment Options in Oncology

Volumn 8, Issue 4, 2007, Pages 305-313

  Elaraj, Dina M ^a   Clark, Orlo H ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CARBONATE; COLESTYRAMINE; FERROUS SULFATE; LIOTHYRONINE; RADIOACTIVE IODINE; SODIUM IODIDE I 131; SUCRALFATE; THYROID HORMONE; THYROXINE;

ADENOMATOUS POLYP; ADJUVANT THERAPY; AGEUSIA; ANTIBIOTIC RESISTANCE; ANXIETY; CANCER CONTROL; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CANCER THERAPY; CARNEY COMPLEX; CERVICAL LYMPH NODE; COWDEN SYNDROME; DIET RESTRICTION; DISEASE COURSE; DRUG MEGADOSE; DRUG WITHDRAWAL; ECHOGRAPHY; FOLLOW UP; FOOD; FOOD DRUG INTERACTION; GARDNER SYNDROME; GASTROINTESTINAL ABSORPTION; HEART ATRIUM CONTRACTION; HEART ATRIUM FIBRILLATION; HEAT INTOLERANCE; HUMAN; HYPERTHYROIDISM; HYPOPARATHYROIDISM; IONIZING RADIATION; LEUKOPENIA; NAUSEA; NERVE INJURY; NODULAR GOITER; OVERALL SURVIVAL; PAPILLARY THYROID CANCER; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; REVIEW; SIDE EFFECT; SUBTOTAL THYROIDECTOMY; TACHYCARDIA; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROID NODULE; THYROIDECTOMY; TREATMENT CONTRAINDICATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, PAPILLARY; CLINICAL TRIALS AS TOPIC; HUMANS; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 38149078035     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-007-0040-2     Document Type: Review

References (35)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66
2. Sherman SI. Thyroid carcinoma. Lancet 2003, 361:501-511
3. SEER Cancer Statistics Review, 1975-2001. National Cancer Institute. http://www.seer.cancer.gov/csr/1975_2001. Accessed August 10, 2007
4. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006, 295:2164-2167
5. Clark OH Papillary thyroid carcinoma: Rationale for total thyroidectomy. In: Clark OH, Duh QY, Kebebew E, eds. Textbook of Endocrine Surgery. 2 Philadelphia: Elsevier Saunders; 2005 110-114
6. Hay ID, Thompson GB, Grant CS, et al.: Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002, 26:879-885
7. Tollin SR, Mery GM, Jelveh N, et al. The use of fine-needle aspiration biopsy under ultrasound guidance to assess the risk of malignancy in patients with a multinodular goiter. Thyroid 2000, 10:235-241
8. Al-Fehaily M, Clark OH Sporadic nontoxic goiter. In: Clark OH, Duh QY, Kebebew E, eds. Textbook of Endocrine Surgery. 2 Philadelphia: Elsevier Saunders; 2005: 24-33
9. Shibata Y, Yamashita S, Masyakin VB, et al.: 15 years after Chernobyl: new evidence of thyroid cancer. Lancet 2001, 358:1965-1966
10. Imaizumi M, Usa T, Tominaga T, et al.: Radiation dose-response relationships for thyroid nodules and autoimmune thyroid diseases in Hiroshima and Nagasaki atomic bomb survivors 55-58 years after radiation exposure. JAMA 2006, 295(9):1011-1022
11. Carling T, Udelsman R Thyroid tumors. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 7 Philadelphia: Lippincott Williams & Wilkins; 2005: 1502-1519
12. Shoup M, Stojadinovic A, Nissan A, et al.: Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg 2003, 197:191-197
13. Haigh PI, Urbach DR, Rotstein LE. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary yhyroidthyroid cancer. Ann Surg Oncol 2005, 12:81-89 81-89
14. Bilimoria KY, Bentrem DJ, Ko CY, et al.: Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 2007, 246(3):375-384
15. Leboulleux S, Rubino C, Baudin E, et al.: Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 2005, 90:5723-5729
16. Thyroid. AJCC Cancer Staging Manual, 6th ed. Edited by Greene F, Page D, Fleming I, et al. Chicago, IL: Springer; 2002:77
17. Comparison Guide: AJCC Staging Manual, Fifth versus Sixth edition. http://www.cancerstaging.org/products/ajccproducts.html#guide. Accessed August 10, 2007
18. Cooper DS, Doherty GM, Haugen BR, et al.: Management guidelines for patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines taskforce. Thyroid 2006, 16(2):109-142
19. Sywak M, Pasieka JL, Ogilvie T. A review of thyroid cancer with intermediate differentiation. J Surg Oncol 2004, 86:44-54
20. Xing M, Westra WH, Tufano RP, et al.: BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005, 90:6373-6379
21. Stulak JM, Grant CS, Farley DR, et al.: Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg 2006, 141:489-496
22. Kouvaraki MA, Shapiro SE, Fornage BD, et al.: Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 2003, 134:946-955
23. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Thyroid Carcinoma v.2.2007. http://www.nccn.org/professionals/ physician_gls/PDF/thyroid.pdf. Accessed August 10, 2007
24. Van Nostrand D, Wartofsky L. Radioiodine in the treatment of thyroid cancer. Endocrinol Metab Clin North Am 2007, 36(3):807-822
25. Meier DA, Brill DR, Becker DV, et al.: Procedure guideline for therapy of thyroid disease with 131 Iodine. J Nucl Med 2002, 43:856-861
26. Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: A reassessment. Nat Clin Pract Endocrinol Metab 2005, 1(1):32-40
27. Leaf AN, Wolf BC, Kirkwood JM, Haselow RE. Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: An Eastern Cooperative Oncology Group Study (E1385). Med Oncol 2000, 17:47-51
28. Mittendorf EA, Wang X, Perrier ND, et al.: Followup of patients with papillary thyroid cancer: In search of the optimal algorithm. J Am Coll Surg 2007, 205:239-247
29. Robbins RJ, Srivastava S, Shaha A, et al.: Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. J Clin Endocrinol Metab 2004, 89:6010-6016
30. Shammas A, Degirmenci B, Mountz JM, et al.: 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 2007, 48(2):221-226
31. Braga-Basaria M, Ringel MD Beyond radioiodine: A review of potential new therapeutic approaches for thyroid cancer. J Clin Endocrinol Metab 2003, 88(5):1947-1960
32. Kebebew E, Reiff E, Greenspan FS, et al.: Rosiglitazone treatment induces radioiodine uptake in some patients with radioiodine-negative thyroglobulin-positive differentiated thyroid cancer [abstract]. The Endocrine Society's 87th Annual Meeting 2005, A-P3-573
33. Smit JW, Shroder-van der Elst JP, Karperien M, et al.: Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line. Thyroid 2000, 10:939-943
34. Smit JW, Schroder-van der Elst JP, Karperien M, et al.: Expression of the human sodium/iodide symporter (hNIS) in xenotransplanted human thyroid carcinoma. Exp Clin Endocrinol Diabetes 2001, 109:52-55
35. ClinicalTrials.gov: Linking patients to medical research. http://www.clinicaltrials.gov. Accessed August 10, 2007